- Home
- PPBT vs CDIO Comparison
PPBT vs CDIO Comparison
Compare PPBT & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- CDIO
- Stock Information
- Founded
- PPBT 2010
- CDIO 2017
- Country
- PPBT Israel
- CDIO United States
- Employees
- PPBT N/A
- CDIO N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- PPBT Health Care
- CDIO Health Care
- Exchange
- PPBT Nasdaq
- CDIO Nasdaq
- Market Cap
- PPBT 6.2M
- CDIO 6.4M
- IPO Year
- PPBT N/A
- CDIO N/A
- Fundamental
- Price
- PPBT $2.31
- CDIO $3.63
- Analyst Decision
- PPBT Strong Buy
- CDIO Buy
- Analyst Count
- PPBT 1
- CDIO 1
- Target Price
- PPBT $33.00
- CDIO $60.00
- AVG Volume (30 Days)
- PPBT 269.4K
- CDIO 41.9K
- Earning Date
- PPBT 08-06-2025
- CDIO 08-14-2025
- Dividend Yield
- PPBT N/A
- CDIO N/A
- EPS Growth
- PPBT N/A
- CDIO N/A
- EPS
- PPBT N/A
- CDIO N/A
- Revenue
- PPBT N/A
- CDIO $19,507.00
- Revenue This Year
- PPBT N/A
- CDIO $1,434.82
- Revenue Next Year
- PPBT N/A
- CDIO $4,661.91
- P/E Ratio
- PPBT N/A
- CDIO N/A
- Revenue Growth
- PPBT N/A
- CDIO N/A
- 52 Week Low
- PPBT $2.00
- CDIO $3.22
- 52 Week High
- PPBT $13.95
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- PPBT 49.88
- CDIO 41.96
- Support Level
- PPBT $2.11
- CDIO $3.58
- Resistance Level
- PPBT $2.31
- CDIO $4.05
- Average True Range (ATR)
- PPBT 0.16
- CDIO 0.33
- MACD
- PPBT 0.01
- CDIO -0.01
- Stochastic Oscillator
- PPBT 72.73
- CDIO 24.74
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.